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ABSTRACT 28 
RATIONALE: We have previously demonstrated that experimental pneumococcal carriage enhances 29 
immunity and protects healthy adults against carriage reacquisition following re -challenge with a 30 
homologous strain. Here we have used a heterologous challenge model to investigate the role of 31 
naturally acquired pneumococcal protein and polysaccharide (PS)-specific immunity in protection 32 
against carriage acquisition.  33 
METHODS: We identified healthy volunteers that were naturally colonised with pneumococcus and, 34 
following clearance of their natural carriage episode, challenged them with a heterologous 6B strain. 35 
In another cohort of volunteers we assessed 6BPS-specific, PspA-specific and PspC-specif ic IgG and 36 
IgA plasma and memory B-cell populations prior to and 7, 14 and 35 days following experimental 37 
pneumococcal inoculation. 38 
RESULTS: Heterologous challenge with 6B resulted in 50% carriage among volunteers with previous 39 
natural pneumococcal carriage. Protection from carriage was associated with a high number of 40 
circulating 6BPS IgG-secreting memory B-cells at baseline. There were no associations between 41 
protection from carriage and baseline levels of 6BPS IgG in serum or nasal wash, PspA-specific or 42 
PspC-specific memory B-cells or plasma cells. In volunteers who did not develop carriage, the 43 
number of circulating 6BPS memory B-cells decreased and the number of 6BPS plasma cells 7 days 44 
post inoculation.  45 
CONCLUSIONS: Our data indicate that naturally acquired polysaccharide-specific memory B-cells, 46 
but not levels of circulating IgG at time of pneumococcal exposure, are associated with protection 47 
against carriage acquisition. 48 
  49 
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INTRODUCTION 50 
Pneumococcal carriage is a pre-requisite of infection and the primary reservoir for transmission (1, 51 
2). Carriage is also an important immunising event in healthy adults and we have previously 52 
demonstrated that experimental carriage protects against reacquisition of carriage after 53 
reinoculation with the same strain (homologous) for up to eleven months following clearance of the 54 
first carriage episode (3).  55 
Animal models have demonstrated that immunoglobulins play a role in host defence against carriage 56 
acquisition (4) and IL-17 secreting CD4+ T-cells play a role in the clearance of carriage (5). While 57 
these immunological responses are well described in murine models, the  immunological responses 58 
which mediate protection in humans have not been identified. We have previously observed that 59 
pneumococcal colonisation increases the level and functional capacity of pneumococcal-specific IgG 60 
and IgA in serum and nasal wash, and that colonisation also increases the number of pneumococcal -61 
specific IL-17 secreting CD4+ T-cells in the lung (3, 6, 7).  62 
Epidemiological data supports the role of polysahccaride (PS)-mediated immunity in protection 63 
against carriage. Vaccination with pneumococcal conjugate vaccine (PCV) has reduced carriage of 64 
vaccine type strains (8), and has resulted in serotype replacement in vaccinated communities (9, 10).  65 
We have recently demonstrated the direct impact of PCV vaccination on pneumococcal carriage 66 
acquisition (11). In a double-blind randomised control trial, the rate of carriage acquisition, following 67 
challenge with 6B pneumococcus, was reduced by 78% in PCV vaccinated volunteers compared with 68 
control vaccinated volunteers. We have previously demonstrated that baseline levels of both PS-69 
specific IgG and capacity for opsonphagocytic killing did not predict carriage outcome following 70 
intranasal pneumococcal inoculation (3, 6, 12). 71 
PS-specific memory B-cells (BMEM) are not present in the mucosal immune tissue of the human 72 
nasopharynx (13). This suggests that the localised stimulation and differentiation of BMEM into plasma 73 
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cells (BPLAS) is unlikely to occur in situ at the mucosa, and that PS-specific immunoglobulin from 74 
systemic circulation may instead mediate protection against carriage acquisition at the mucosal 75 
surface.  76 
Here we identified healthy volunteers that were naturally colonised with pneumococcus and 9 to 16 77 
months following clearance of their carriage episode challenged them with a heterologous 78 
pneumococcal serotype, resulting in a 50% rate of carriage. We have previously demonstrated 0% 79 
carriage reacquisition up to 11 months following a carriage episode when re-challenged with the 80 
same strain (3). We further assessed B-cell-mediated immunity among volunteers with no current 81 
pneumococcal carriage and an unknown history of previous pneumococcal carriage exposure. We 82 
observed that volunteers protected from carriage (carriage-negative) had similar levels of circulating 83 
IgG but higher number of PS-specific BMEM than volunteers susceptible to carriage (carriage-positive). 84 
Responses to protein-based antigens were not associated with protection against carriage. Taken 85 
together these data suggest that naturally acquired PS-specific immunity plays a prominent role  in 86 
mediating protection against acquisition of pneumococcal carriage in unvaccinated volunteers.  87 
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MATERIALS AND METHODS 88 
Ethical approval, study protocol and sampling 89 
8 healthy non-smoking adult volunteers aged between 18 and 60 years, who had a confirmed 90 
previous natural carriage episode, and who had no close contact with risk individuals were recruited  91 
to cohort A. 24 healthy non-smoking adults aged between 18 and 60 years, who had no current 92 
pneumococcal carriage and an unknown history of pneumococcal exposure, and who had no close 93 
contact with at-risk individuals were recruited to cohort B. Written informed consent was obtained 94 
from all volunteers. Both studies were approved by the National Research Ethics Service 95 
(11/NW/0592) and were sponsored by the Royal Liverpool and Broadgreen University Hospitals 96 
Trust.  97 
In cohort A, each volunteer was inoculated with 35375 ± 2651 colony-forming units (cfu) per naris of  98 
S. pneumoniae serotype 6B (strain BHN418) (14) (Table 1). In cohort B, each volunteer was 99 
inoculated with 61944 ± 4603 cfu/naris of S. pneumoniae serotype 6B (Table 1). Bacterial 100 
preparation and inoculation, as well as nasal wash sampling and carriage detection were performed 101 
as previously described (15). In cohort A, nasal wash samples were obtained 5 days prior to 102 
intranasal inoculation and then on days 2, 7 and 14 following inoculation. Peripheral blood samples 103 
were obtained 5 days prior to intranasal inoculation and then 14 days following inoculation. In 104 
cohort B, nasal wash samples were obtained 5 days prior to intranasal inoculation and then on days 105 
2, 7, 14, 21, 28 and 35 following inoculation. Peripheral blood samples were obtained 5 days prior to 106 
intranasal inoculation and then on days 7, 14 and 35 days following inoculation.  107 
Anti-pneumococcal capsular polysaccharide ELISA 108 
Anti-pneumococcal capsular polysaccharide (PS) antibodies were determined using the World Health 109 
Organisation internationally standardised method and reagents (16). For full details, please refer to 110 
Supplementary Materials and Methods. 111 
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Opsonophagocytic killing assay (OPKA) 112 
OPKA assays were performed as previously described(3), with minor modifications. For ful l  detai ls, 113 
please refer to Supplementary Materials and Methods. 114 
Preparation of Enzyme-linked immunosorbent spot (ELISpot) plates 115 
Wells of ELISpot plates (multiscreen IP 96-well filter plates; Millipore) were coated with 100µL 116 
Dulbecco's PBS-/- (DPBS) supplemented with either anti-IgG (1:50; total IgG), anti-IgA (1:50; total IgA)  117 
20µg/mL 6BPS, 2µg/mL PspA, 2µg/mL PspC, influenza (1:50; positive control, unpublished data) or 118 
unsupplemented DPBS (negative control). Coated plates were stored at 4˚C for up to 48 hours. 24 119 
hours prior to use, ELISpot plates were brought to room temperature and washed six times with 120 
DPBS. Plates were blocked with RPMI-1640 supplemented with 2% BSA for two hours. Plates were 121 
then washed six times with DPBS. 122 
Plasma cell (BPLAS) detection 123 
Peripheral blood mononuclear cells (PBMCs) were isolated using Histopaque®-1077 (Sigma-Aldrich) , 124 
according to the manufacturers instructions. For full details, please refer to Supplementary Materials 125 
and Methods. Cells were seeded in ELISpot plates in 100µL volumes, in complete medium, in 126 
triplicate, at a concentration of either 5 × 106 cells/mL (6BPS, PspA, PspC) or 5 × 105 cells/mL (total 127 
IgG, total IgA, positive control, negative control). Plates were incubated for sixteen hours at 37°C in 128 
5% CO2. For detection of IgG, plates were washed six times with 0.05% PBS-tween and incubated 129 
with 1:2,000 anti-human-IgG-alkaline-phosphatase (Sigma-Aldrich) for two hours. For detection of  130 
IgA, plates were washed six times with 0.05% PBS-tween and incubated with 1:2,000 anti-human-IgA 131 
(AbD Serotec) for two hours. Plates were then washed a further six times with 0.05% PBS-tween and 132 
incubated with 1:2,000 streptavidin:alkaline phosphatase (AbD Serotec) for one hour. For detection 133 
of both IgG and IgA, plates were washed six times with 0.05% PBS-tween and incubated with 100µL 134 
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p-nitrophenyl phosphate (pNPP; Sigma-Aldrich). Plates were washed six times with distilled H2O and 135 
then stored in the absence of light. 136 
Memory B-cell (BMEM) detection 137 
2.5 × 106 cells/mL were seeded in 6-well plates, in complete medium supplemented with 1:2,500 138 
Staphylococcus aureus Cowan strain (SAC), 1:3,000 pokeweed mitogen (PWM; Sigma-Aldrich),  and 139 
1:40 CpG oligonucleotide (ODN-2006; TCG-TCG-TTT-TGT-CGT-TTT-GTC-GTT; InvivoGEN). Plates were 140 
incubated for seven days at 37°C in 5% CO2. Cells were harvested, washed in complete medium and 141 
the cell concentration determined using an Improved Neubauer Haemocytometer (CamLab). Cel ls 142 
were then seeded in ELISpot plates in 100µL volumes, in comple te medium, in triplicate, at a 143 
concentration of either 5 × 106 cells/mL (6BPS, PspA, PspC) or 5 × 105 cells/mL (total IgG, positive 144 
control, negative control). Plates were incubated for sixteen hours at 37°C in 5% CO 2. Plates were 145 
washed six times with 0.05% PBS-tween and incubated with 1:2,000 anti-human-IgG-alkaline-146 
phosphatase for two hours. Plates were washed six times with 0.05% PBS-tween and incubated with 147 
100µL pNPP (Sigma-Aldrich). Plates were washed six times with distilled H2O and then stored in the 148 
absence of light. 149 
ELISpot counting 150 
ELISpot data were acquired using an AID ELISpot Reader (ELR02) and the data analysed using AID 151 
ELISpot Software v3.3 (Cadama Medical). Identical settings were used for the analysis of all wells. Al l 152 
plates were manually verified and any artefacts removed by an operator who was blinded for the 153 
ELISpot condition, the carriage status of each volunteer and the sampling time point.  154 
Statistical analyses  155 
All statistical analyses were performed using SPSS v22 (IBM) and all P values are two-tai led. Where 156 
appropriate, data were logarithmically transformed for purposes of statistical analyses. Comparisons 157 
were made between carriage-positive and carriage-negative groups using unpaired t tests; 158 
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differences were considered significant at P≤0.05. Multiple comparisons were made within carriage -159 
positive and carriage-negative groups using paired t tests with manual Bonferroni correction 160 
(significance level α=0.05 with number of tests n=3); differences were considered significant at 161 
P<0.0166.  162 
  163 
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RESULTS 164 
Natural episodes of pneumococcal carriage do not protect against heterologous challenge 165 
In order to determine the role of naturally acquired serotype-specific immunity in protection against 166 
carriage acquisition we identified a cohort of 8 healthy volunteers (cohort A) that were naturally 167 
colonised with pneumococcus and, following clearance, experimentally challenged them with a 168 
heterologous strain.  169 
We observed that heterologous inoculation with 6B pneumococcus 9 to 16 months following 170 
clearance of natural carriage resulted in 50% carriage (Table 1 and 2). In another cohort of 24 171 
volunteers (cohort B), with no current pneumococcal carriage and unknown history of 172 
pneumococcal exposure, inoculation with 6B pneumococcus resulted in 42%  carriage (Table 1). 173 
This is consistent with the 40-60% carriage rates observed in our previous studies where uncolonised 174 
volunteers were inoculated with doses of 6B pneumococcus ranging between 40,000-130,000 175 
cfu/naris (3).  176 
Levels of 6BPS IgG and IgA in serum and nasal wash are not associated with protection against 177 
carriage acquisition 178 
We assessed levels of pneumococcal antibody and B-cells in cohort B. Levels of 6BPS IgG in serum at 179 
baseline (day -5) were similar in carriage-positive volunteers (those that were susceptible to 180 
carriage) and carriage-negative volunteers (those that were protected against carriage)  ( Figure 1A; 181 
median [interquartile range (IQR)]: 1.0µg/mL [0.6-1.6] versus 0.9µg/mL [0.5-1.4]). In carriage-182 
positive volunteers, post inoculation levels of 6BPS IgG were comparable at day 7 (1.1µg/mL [0.6-183 
2.0]), but were significantly higher at day 14 (1.3µg/mL [0.8-3.8]; P=0.001) and day 35 (2.5µg/mL 184 
[1.2-5.8]; P=0.001) than at baseline. In carriage-negative volunteers levels of 6BPS IgG in serum 185 
following inoculation were comparable to those at baseline.  Levels of 6BPS IgG in nasal wash at 186 
baseline were similar in carriage-positive volunteers and carriage-negative volunteers (Figure 1B; 187 
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1.0ng/mL [0.8-2.4] versus 0.7ng/mL [0.6-0.8]). In both groups levels of 6BPS IgG in nasal wash 188 
following inoculation were comparable to those at baseline. 189 
Levels of 6BPS IgA in serum at baseline were higher in carriage-positive volunteers than in carriage -190 
negative volunteers (Figure S1A; 0.5µg/mL [0.4-0.6] versus 0.3µg/mL [0.2-0.4]; P=0.001). In carriage -191 
positive volunteers, post inoculation levels of 6BPS IgA were comparable at day 7 (0.5µg/mL [0.4-192 
0.6]), significantly higher day 14 (0.8µg/mL [0.5-1.9]; P=0.005) but were not significantly higher at 193 
day 35 (0.7µg/mL [0.5-1.5]) than at baseline. In carriage-negative volunteers levels of 6BPS IgA in 194 
serum following inoculation were comparable to those at baseline. Levels of 6BPS IgA in nasal  wash 195 
were similar in carriage-positive volunteers and carriage-negative volunteers between both groups 196 
at baseline (Figure S1B; 18.3ng/mL [12.0-45.0] versus 14.0ng/mL [6.9-16.4]) and were unchanged 197 
following challenge. 198 
We assessed whether the capcity of antibodies in mediating phagocytosis was associated with 199 
protection. No difference was between carriage-negative volunteers compared with carriage-200 
positive volunteers at baseline (Figure S2).  201 
High baseline number of 6BPS IgG-secreting BMEM is associated with protection against carriage 202 
acquisition 203 
At baseline, the number of 6BPS IgG-secreting BMEM in carriage-positive volunteers was 204 
approximately three-times lower than that in carriage-negative volunteers (Figure 2A; 12.3 [9.4-205 
25.4] versus 32.1 [14.9-86.4]; P=0.042). Post inoculation, in carriage-positive volunteers, the 206 
numbers of 6BPS IgG-secreting BMEM at day 7 (15.0 [4.4-46.8]), day 14 (15.6 [5.4-24.9]) and day 35 207 
(7.0 [5.6-30.0]) was comparable to those at baseline. In carriage-negative volunteers, the number of  208 
6BPS IgG-secreting BMEM was not significantly lower at day 7 (8.3 [5.7-16.4]) or day 14 (11.8 [8.4-209 
26.7]; P=0.03) but was significantly lower at day 35 (5.9 [3.4-11.4]; P=0.012) compared to baseline. 210 
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At baseline, the number of 6BPS IgG-secreting BPLAS was not different in carriage-positive volunteers 211 
compared with carriage-negative volunteers (Figure 2B; 3.0 [1.8-37.8] versus 5.3 [0.5-14.9]). Post 212 
inoculation, in carriage-positive volunteers, the number of 6BPS IgG-secreting BPLAS were not 213 
significantly different to those at baseline. In carriage-negative volunteers, the number of 6BPS IgG-214 
secreting BPLAS was approximately four-times higher at day 7 (83.5 [45.6-135.3]; P=0.006) compared 215 
to baseline, returning to a comparable level at day 14 (3.3 [1.0-9.0]) and day 35 (7.3 [2.5-13.3]). 216 
Baseline number of PspA and PspC IgG-secreting BMEM are not associated with protection against 217 
carriage acquisition 218 
At baseline, the number of PspA IgG-secreting BMEM was not different in carriage-positive volunteers 219 
compared with carriage-negative volunteers (Figure 3A). In both groups numbers of PspA IgG-220 
secreting BMEM following inoculation were comparable to those at baseline. 221 
At baseline, the number of PspA IgG-secreting BPLAS was not different in carriage-positive volunteers 222 
compared with carriage-negative volunteers (Figure 3B; 25.5 [9.8-36.2] versus 13.8 [4.5-71.8]) .  Post 223 
inoculation, in carriage-positive volunteers, the number of PspA IgG-secreting BPLAS was not 224 
significantly higher at day 7 (50.7 [31.0-84.7]) or day 14 (79.2 [25.8-141.6]) but was significantly 225 
higher at day 35 (74.8 [67.7-79.6]; P=0.005) compared to baseline. In carriage-negative volunteers 226 
the numbers following inoculation were comparable to those at baseline. 227 
At baseline, the number of PspC IgG-secreting BMEM was not different in carriage-positive volunteers 228 
compared with carriage-negative volunteers (Figure 4A). In both groups the numbers following 229 
inoculation were comparable to those at baseline. 230 
At baseline, the number of PspC IgG-secreting BPLAS was not different in carriage-positive volunteers 231 
compared with carriage-negative volunteers (Figure 4B; 3.2 [1.7-40.6] versus 9.5 [4.1-15.1]). Post 232 
inoculation, in carriage-positive and carriage-negative volunteers, the number of PspC IgG-secreting 233 
BPLAS were not significantly different to those at baseline. 234 
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Baseline number of PS IgG-secreting BMEM are not associated with levels of PS IgG in serum 235 
Since we observed that a high baseline number of 6BPS IgG-secreting BMEM was associated with 236 
protection, and that the number of IgG BPLAS were increased following inoculation in carriage 237 
negative volunteers, we analysed whether the number of 6BPS IgG-secreting BMEM at baseline or the 238 
number of 6BPS IgG-secreting BPLAS at day 7 were associated with increased levels of 6BPS IgG in 239 
serum post inoculation.  240 
Unadjusted linear regression analysis revealed that the baseline number of 6BPS IgG-secreting BM EM  241 
did not correlate with the area under the curve (AUC) of 6BPS IgG in serum (data not shown). There 242 
was also no correlation between the increase in 6BPS IgG-secreting BPLAS at day 7 and the AUC of 243 
6BPS IgG or the absolute number of 6BPS IgG in serum at any time point (data not shown). 244 
No correlation was observed between the increase in 6BPS IgG BPLAS at any time point or AUC of 245 
6BPS IgG and colonisation intensity (density and duration; AUC) over the 35 day study period (data 246 
not shown).  247 
Baseline number of 6BPS, PspA and PspC IgA-secreting BMEM or BPLAS are not associated with 248 
protection against carriage acquisition 249 
At baseline, the number of 6BPS IgA-secreting BMEM and BPLAS were not different in carriage-posi tive 250 
volunteers compared with carriage-negative volunteers (Figure S3A). In both groups the numbers of  251 
6BPS IgA-secreting BMEM and BPLAS following inoculation were comparable to those at baseline. 252 
At baseline, the number of PspA IgA-secreting BMEM and BPLAS were not significantly different in 253 
carriage-positive volunteers compared with carriage-negative volunteers (Figure S4A; 2.7 [1.5-4.7]  254 
versus 3.9 [1.4-4.4] and Figure S2B; 26.9 [5.0-47.5] versus 6.1 [4.2-10.6]). Post-incoulation, in 255 
carriage-positive and carriage-negative volunteers, the number of PspA IgA-secreting BPLAS were not 256 
significantly different to those at baseline. 257 
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At baseline, the number of PspC IgA-secreting BMEM was not different in carriage-positive volunteers 258 
compared with carriage-negative volunteers (Figure S5A). In both groups the numbers following 259 
inoculation were comparable to those at baseline.  260 
At baseline, the number of PspC IgA-secreting BPLAS was higher in carriage-positive volunteers than in 261 
carriage-negative volunteers (Figure S5B; 46.5 [13.3-103.8] versus 4.1 [3.0-9.4]; P=0.025). Post-262 
inoculation, in carriage-positive and carriage-negative volunteers, the number of PspC IgA-secreting 263 
BPLAS were not significantly different to those at baseline.  264 
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DISCUSSION 265 
Using our experimental human pneumococcal carriage model and heterologous challenge of 266 
previously colonized volunteers we have demonstrated that PS-specific, but not protein-specif ic,  B-267 
cell mediated immunity is associated with protection against carriage acquisition. Specifically, we 268 
observed that a high number of PS IgG-secreting BMEM rather than PS6B IgG levels was associated 269 
with protection against carriage. 270 
It is well established that antibody-mediated immune responses targeting serotype-specific 271 
polysaccharides protect against pneumococcal disease (17). Serotype replacement, which has been 272 
observed following the introduction of PCV, highlights the role of PS-mediated immunity in 273 
protection against carriage (8, 11). We have previously demonstrated 0% carriage acquisition 274 
following re-challenge with a homologous strain up to 11 months following clearance of the first 275 
carriage episode (3). Here we demonstrate that heterologous challenge results in a 50% rate of 276 
carriage, which is similar to the carriage rates observed in our previous studies in which volunteers 277 
with no current pneumococcal carriage and an unknown history of previous pneumococcal exposure  278 
were challenged with a 6B strain (3, 11). This supports the hypothesis that PS-specific immunity 279 
plays an important role in protection against carriage.  280 
Following on from heterologous challenge experiments, we  assessed B-cell mediated PS-specific 281 
immunity in another cohort of 24 volunteers with no current pneumococcal carriage and an 282 
unknown history of previous pneumococcal exposure . There was no association between the 283 
functional capacity of serum antibody, nor number of PspA- or PspC BMEM or BPLAS and protection 284 
against carriage. We did, however, observe that a high number of circulating PS IgG-secreting BM EM  285 
at baseline was associated with protection against experimental carriage acquisition.  286 
Among volunteers protected against carriage, the number of circulating PS IgG-secreting BMEM was 287 
dramatically reduced and the number of PS-specific IgG-secreting BPLAS increased 7 days post 288 
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inoculation. Expansion of the PS IgG-secreting BPLAS population was relatively short-lived and 289 
returned to baseline levels 14 days following inoculation. These data are consistent with a rapid 290 
differentiation of PS IgG-secreting BMEM into short-lived BPLAS. A similar effect has been observed and 291 
implicated in immunity to malaria (21).  292 
Among carriage-negative volunteers, the increased number of circulating PS IgG-secreting BP L AS was 293 
not accompanied by increased levels of PS IgG in serum or nasal wash. For this reason we 294 
hypothesise that antibodies produced by these plasma cells bind to the inoculated bacteria in the 295 
nasopharynx, facilitating bacterial agglutination, impairing bacterial adherence and leading to 296 
protection from colonisation acquisition. In carriage-positive volunteers, levels of PS IgG and IgA in 297 
serum were higher at day 14 than at baseline – this response is likely generated through 298 
immunisation by colonisation rather than an acute response to inoculation. We observed that 299 
baseline levels of PS IgA in serum were higher in volunteers that were susceptible to colonisation. 300 
We have previously observed a similar association between susceptibility and increased levels of IgG 301 
to LytC, PcsB SP0609, SPR0057 and SPR2021 (3). This may be an indication of an underlying 302 
suceptability to pneumocccal carriage, with elevated serum immunoglobulin indicative of repeated 303 
exposure. 304 
While it is well established that repeated exposure to pneumococci is required for the maintenance 305 
of IgG-secreting BMEM populations, more recently it has been suggested that exposure during life also 306 
enhances the adult immune response to PCV (22). A similar effect has been observed in the UK, 307 
where lack of Haemophilus influenzae type B carriage led to an increased incidence of disease 308 
among children who received a single dose of Hib vaccine(23).  309 
Based on data presented here, we postulate that: [1] pneumococcal nasal inoculation results in the  310 
rapid expansion of pre-existing PS-specific BMEM into short-lived IgG-secreting BPLAS. Expansion of BPLAS 311 
results in increased PS-specific antibody production; these antibodies bind to the inoculated bacteria 312 
at the nasopharynx resulting in bacterial agglutination and protection from colonisation acquisition. 313 
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[2] Although pneumococcal colonisation is immunising, adsorption of antibody by bacteria in the 314 
nasopharynx may prevent the detection of increased antibody production promoted by exposure to 315 
pneumococcus. [3] Only if colonisation is established BPLAS continue to circulate in high number, 316 
continued stimulation and antibody production eventually leads to the detection of  increased PS-317 
specific serum IgG as the bacteria are cleared from the nasopharynx. We are currently investigating 318 
the impact of nasal antibody-mediated agglutination and its role in protection against pneumococcal 319 
carriage acquisition in PCV vaccinated volunteers. 320 
IgA plays a prominant role in defence at the mucosal surface; it is involved in controlling invasive 321 
pneumococcal diseases (24) and the regulation of S. pneumoniae colonisation in the nasal  cavi ty of  322 
mice (25). We did not observe an association between the number in 6BPS IgA-secreting B-cell 323 
populations and protection against carriage acquisition, indicating that the peripheral assessment of  324 
IgA-secreting populations may not reflect the activity of IgA populations at the mucosa. IgA1 325 
accounts for approximately 90% of all IgA found in peripheral blood and the upper respiratory tract 326 
(18, 19). Streptococcus pneumoniae is able to cleave IgA1, via IgA1 protease, a mechanism that 327 
facilitates pneumococcal adherence to the epithelium and abrogates the protective effects of IgA 328 
(20). As a result, we hypothesise that protection against colonisation was associated with PS IgG-329 
secreting BMEM populations rather than PS IgA-secreting BMEM populations due to the advantage 330 
conferred through the generation of IgG rather than IgA based responses.  331 
The strength of this study is the use of a unique experimental human pneumococcal challenge model 332 
with multiple assessments of B-cell populations in blood, and antibodies in serum and in nasal  wash 333 
samples; this model allows us to study carriage and its associated immunological responses with a 334 
known exposure time point. One weakness of this study is that our results propose an important 335 
mechanism of protection but do not exclude the possibility that other immune cell populations, or 336 
responses targeting alternate antigens may also contribute towards protection against carriage 337 
acquisition. 338 
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Data presented here has important implications for the future of pneumococcal vaccine 339 
development, as it is likely that PS-mediated immunity is required for high levels of protection 340 
against carriage acquisition. Several protein-based vaccines are currently in development and i t wi l l  341 
be important to assess whether these vaccines will impact carriage both directly, in immunised 342 
volunteers, and indirectly, via a herd effect, as observed for PCV vaccines (8, 11, 26) .  The  role  of  T-343 
cell responses in the control of carriage density and in clearance of carriage suggests that protein-344 
based vaccines capable of inducing this type of immunity may offer several advantages over 345 
currently licensed vaccines, facilitating control of carriage intensity (density and duration), whilst 346 
maintaining the opportunity for immunisation through natural  carriage acquisition (5, 27, 28). 347 
Specifically, it is possible that protein-based vaccines could prevent pneumonia and invasive 348 
pneumococcal disease while maintaining the opportunity for further immunisation during natural  349 
episodes of carriage. We have previously demonstrated the protective effect of PCV-13 on 350 
pneumococcal carriage (11). We have now demonstrated that PS-mediated naturally acquired 351 
immunity is a key mediator of protection against carriage acquisition.   352 
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Figure 1: Kinetics of polysaccharide 6B IgG. IgG specific ELISAs in serum (A) and nasal wash (B) were 440 
performed against pneumococcal 6B polysaccharide (PS6B). Levels of antibody were determined 441 
using serum and nasal wash samples from carriage-positive (carriage +) and carriage-negative 442 
(carriage -) volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Nasal wash 443 
samples were obtained prior (day -5) and post inoculation (day 7, day 2, day 14 and day 35) . Serum 444 
samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35). The box in the 445 
upper right section shows data collected prior to (day -5) and post (day 14) challenge for those 446 
volunteers who underwent heterologous challenge (cohort A). Horizontal bars represent median 447 
values and bars represent the interquartile range.   448 
Figure 2. Kinetics of polysaccharide 6B IgG-producing B-cell populations. ELISpots were performed 449 
against pneumococcal polysaccharide 6B (PS6B). The number of IgG-producing memory B-cells 450 
(BMEM) (A) and plasma cells (BPLAS) (B) were determined using blood samples from carriage-posi tive 451 
(carriage +) and carriage-negative (carriage -) volunteers. Samples were obtained prior (day  -5)  and 452 
post inoculation (day 7, day 14 and day 35) from healthy volunteers experimentally inoculated with 453 
Streptococcus pneumoniae 6B. Horizontal bars represent median values and bars represent the 454 
interquartile range.   455 
Figure 3. Kinetics of PspA IgG-producing B-cell populations. ELISpots were performed against PspA.  456 
The number of IgG-producing memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were determined 457 
using blood samples from carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. 458 
Samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35) from healthy 459 
volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent 460 
median values and bars represent the interquartile range.   461 
Figure 4. Kinetics of PspC IgG-producing B-cell populations. ELISpots were performed against PspC.  462 
The number of IgG-producing memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were determined 463 
using blood samples from carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. 464 
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Samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35) from healthy 465 
volunteers experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent 466 
median values and bars represent the interquartile range.   467 
Supplementary Figure 1. Kinetics of polysaccharide 6B IgA. IgA specific ELISAs in serum (A) and 468 
nasal wash (B) were performed against pneumococcal 6B polysaccharide (PS6B). Levels of antibody 469 
were determined using serum and nasal wash samples from carriage-positive (carriage +) and 470 
carriage-negative (carriage -) volunteers experimentally inoculated with Streptococcus pneumoniae  471 
6B. Nasal wash samples were obtained prior (day -5) and post inoculation (day 7, day 2, day 14 and 472 
day 35). Serum samples were obtained prior (day -5) and post inoculation (day 7, day 14 and day 35). 473 
The box in the upper right section shows data collected prior to (day -5) and post (day 14) challenge 474 
for those volunteers who underwent heterologous challenge (cohort A). Horizontal bars represent 475 
median values and bars represent the interquartile range.  476 
Supplementary Figure 2. Opsonophagocytic activity of serum antibodies at baseline against 6B. 477 
The functional capacity of antibody against Streptococcus pneumoniae 6B was determined using 478 
heat-inactivated serum samples from carriage-positive (carriage +) and carriage-negative (carriage -)  479 
volunteers. The percentage of killing is shown for 3  (1 in 3, 1 in 9 and 1 in 27) . Horizontal bars 480 
represent median values and bars represent the interquartile range.  481 
Supplementary Figure 3. Kinetics of polysaccharide 6B IgA-producing B-cell populations. ELISpots 482 
were performed against pneumococcal polysaccharide 6B (6BPS). The number of IgA-producing 483 
memory B-cells (BMEM) (A) and plasma cells (BPLAS) (B) were determined using blood samples from 484 
carriage-positive (carriage +) and carriage-negative (carriage -) volunteers. Samples were obtained 485 
prior (day -5) and post inoculation (day 7, day 14 and day 35) from healthy volunteers 486 
experimentally inoculated with Streptococcus pneumoniae 6B. Horizontal bars represent median 487 
values and bars represent the interquartile range.  488 
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Supplementary Figure 4. Kinetics of PspA IgA-producing B-cell populations. ELISpots were 489 
performed against PspA. The number of IgA-producing memory B-cells (BMEM) (A) and plasma cel l s 490 
(BPLAS) (B) were determined using blood samples from carriage-positive (carriage +) and carriage-491 
negative (carriage -) volunteers. Samples were obtained prior (day -5) and post inoculation (day 7, 492 
day 14 and day 35) from healthy volunteers experimentally inoculated with Streptococcus 493 
pneumoniae 6B. Horizontal bars represent median values and bars represent the interquartile range.   494 
Supplementary Figure 5. Kinetics of PspC IgA-producing B-cell populations. ELISpots were 495 
performed against PspC. The number of IgA-producing memory B-cells (BMEM) (A) and plasma cells 496 
(BPLAS) (B) were determined using blood samples from carriage-positive (carriage +) and carriage-497 
negative (carriage -) volunteers. Samples were obtained prior (day -5) and post inoculation (day 7, 498 
day 14 and day 35) from healthy volunteers experimentally inoculated with Streptococcus 499 
pneumoniae 6B. Horizontal bars represent median values and bars represent the interquartile range.   500 
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Table 1: Participants of heterologous challenge and traditional challenge cohorts 501 
 502 
Study 
Number of 
Volunteers 
Age 
(years) 
Sex (M:F) 
Study 
Period 
Dose 
(cfu/naris) 
Experimental 
Carriage Rate 
Cohort A 
(heterologous 
challenge) 
8 28 ± 14 4:4 
Feb 2013 - 
Mar 2013 
35375 ± 2651 50% (4/8) 
Cohort B 
(challenge) 
24 23 ± 3 9:15 
Sep 2012-
Nov 2012 
61944 ± 4603 42% (10/24) 
 
     Table 2: Pre-existing serotypes and carriage status of heterologous challenge cohort (cohort A) 503 
Subject Serotype Carriage 
Time between carriage episode 
and re-challenge (months) 
1 6 No 14 
2 3 No 11 
3 33 No 9 
4 3 No 13 
5 33 Yes 16 
6 19 Yes 11 
7 15 Yes 14 
8 33 Yes 11 
  504 
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SUPPLEMENTARY MATERIALS AND METHODS 505 
Anti-pneumococcal capsular polysaccharide ELISA 506 
Anti-pneumococcal capsular polysaccharide (PS) antibodies were determined by using the WHO 507 
internationally standardised method and reagents (16). Briefly, 96-well ELISA plates were coated 508 
using 5μg/mL of purified 6BPS (Statens Serum Institute) for 5 hours at 37°C. Wells were blocked with 509 
10% foetal bovine serum in PBS (PBS-F) for 1 hour at 37°C. Plates were washed 3 times with PBS 510 
containing 0.05% Tween-20 between each step. Samples were diluted in PBS-F containing 10g/mL 511 
CWPS Multi (Statens Serum Institute) and incubated for 30 minutes at 37°C. 89-SF5 reference serum 512 
received from U.S. Food and Drug Administration was used as a standard. Diluted/adsorbed samples 513 
were then transferred to pre-coated plates and incubated overnight at 4°C. Antibody detection was 514 
performed as described for anti-pneumococcal protein ELISA. All samples were run in triplicate in 515 
four dilutions, and samples with a CV of greater than 15% were repeated. Results are  expressed as 516 
µg/mL calculated using the assigned IgG concentrations in reference serum 89-SF5. 517 
Opsonophagocytic killing assay (OPKA) 518 
Heat-inactivated serum samples were diluted 1:3, 1:9 and 1:27 in opsonisation buffer B (OBB). A 519 
control standard was created using heat-inactivated 89SF serum diluted 1:3, 1:9, 1:27, 1:81, 1:243, 520 
1:729, 1:2,187 and 1/6561 in OBB. Serum and control samples were then added to the wells of a 96-521 
well U-bottom plate (Costar). Streptococcus pneumoniae 6B were washed, resuspended in Hanks' 522 
Balanced Salt Solution (HBSS)+/+, and added to wells, as required, at concentration of 1 × 103 523 
cfu/well. Plates were then incubated at 37°C for 20 minutes with shaking (300 r.p.m). 10% 524 
complement and 1 × 105 THP- 1 cells were added separately to wells, as required (multiplicity of 525 
infection 100:1 [cells:bacteria]). Plates were then incubated at 37°C for 60 minutes with shaking (300 526 
r.p.m). 527 
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Control wells were included which contained THP-1 cells, bacteria and complement, without a 528 
source of antibody. Additional control wells containing heat-inactivated complement were also 529 
included. 530 
Following incubation, plates were placed on ice for 10 minutes. 10µl of the suspension from each 531 
reaction was then plated in triplicate onto horse blood agar plates (Oxoid). Plates were then 532 
incubated overnight at 37°C with 5% CO2. The serum killing index was determined by comparing cfu 533 
recovered from serum treated wells with that from control wells. 534 
Peripheral blood mononuclear cell (PBMC) isolation 535 
Peripheral blood samples were collected in lithium heparin VacutainersTM (BD Biosciences). Samples 536 
were diluted with an equal volume of Dulbecco's PBS-/- (DPBS; Invitrogen) and PBMCs isolated by 537 
differential centrifugation using Histopaque®-1077 (Sigma-Aldrich). Cells were washed twice in 538 
DPBS, re-suspended in complete medium (RPMI-1640 supplemented with 10% FBS and 2% 200mM 539 
L-glutamine; Invitrogen), and the cell concentration determined using an Improved Neubauer 540 
Haemocytometer (CamLab). Samples were stored on ice for use in downstream applications. 541 
